×
About 10,770 results

ALLMedicine™ Alopecia Center

Research & Reviews  3,243 results

Algorithm proposal for hair transplantation in fibrosing alopecia pattern distribution.
https://doi.org/10.1111/jocd.15124
Journal of Cosmetic Dermatology; Gómez-Zubiaur A, Valenzuela C et. al.

May 28th, 2022 - Algorithm proposal for hair transplantation in fibrosing alopecia pattern distribution.|2022|Gómez-Zubiaur A,Valenzuela C,Andrés-Lencina JJ,Rodríguez-Villa A,Ricart JM,|

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04784533

May 27th, 2022 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

Trichorrhexis Nodosa
https://emedicine.medscape.com/article/1073664-overview

May 26th, 2022 - Practice Essentials The essential abnormality of trichorrhexis nodosa is the formation of nodes along the hair shaft through which breakage readily occurs. In 1852, Samuel Wilks of Guy's Hospital first described the condition, although the term tr...

Clinical observation and evaluation of CGF in the treatment of androgenic alopecia.
https://doi.org/10.1111/jocd.15109
Journal of Cosmetic Dermatology; Zhao F, Hao L et. al.

May 25th, 2022 - To evaluate the efficacy of concentrated growth factor (CGF) injections in patients with androgenic alopecia. Venous blood of 60 patients(aged 18-55 years old with a mean age of 38 years) with androgenic alopecia who were treated from September 20...

Pituitary effects of metformin in men with early-onset androgenic alopecia.
https://doi.org/10.1002/jcph.2088
Journal of Clinical Pharmacology; Krysiak R, Kowalcze K et. al.

May 24th, 2022 - Males with early-onset androgenic alopecia are characterized by elevated androgen levels. The aim of the present study was to investigate whether the presence of this condition modulates the impact of metformin on pituitary hormone production. Thi...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  296 results see all →

Clinicaltrials.gov  153 results

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04784533

May 27th, 2022 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
https://clinicaltrials.gov/ct2/show/NCT03474718

May 23rd, 2022 - Androgenic alopecia, or male-pattern hair loss affects both men and women. This hair loss pattern is typically characterized by thinning at the crown of scalp and/or M-shaped hair line in males or diffuse thinning throughout in females. Platelet-r...

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
https://clinicaltrials.gov/ct2/show/NCT01889199

May 18th, 2022 - Aim 1. Examine mechanisms of subcutaneous abdominal adipose (fat) development in normal-weight PCOS women vs. BMI- and age-matched normal (control) women. Subjects and clinical assessment: We will recruit 16 lean (18.5-25 kg/M2) PCOS subjects and ...

Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05051761

May 18th, 2022 - This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called Jaktinib) in adults (≥18 years and <65 years) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning ...

CU-40101-101 Following a Fixed-volume Topical Single Administration in Healthy Male Subjects With Androgenetic Alopecia
https://clinicaltrials.gov/ct2/show/NCT05380427

May 18th, 2022 - To evaluate the safety and tolerability of TDM-105795 administered topically in healthy male subjects with androgenetic alopecia(AGA ). To evaluate the pharmacokinetics (PK)/Pharmacodynamics (PD) of TDM-105795 following administration of a single ...

see more →

News  601 results

European committee recommends approval of baricitinib for severe alopecia areata
https://www.mdedge.com/dermatology/article/254805/hair-nails/european-committee-recommends-approval-baricitinib-severe
Doug Brunk

May 20th, 2022 - The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata (AA). The development, whi.

Baricitinib Recommended for Approval of Severe Alopecia Areata in Europe
https://www.medscape.com/viewarticle/974368

May 20th, 2022 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata (AA). The development, whi...

Baricitinib Promotes Hair Growth in Alopecia Areata
https://www.medscape.com/viewarticle/973864

May 12th, 2022 - Core Messages Two phase 3 studies, each running for 36 weeks, have proven the efficacy of the Janus kinase inhibitor baricitinib (Olumiant) for patients with alopecia areata. Almost a quarter of participants achieved the therapeutic aim of 80% hai...

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer
https://www.onclive.com/view/nab-paclitaxel-plus-pembrolizumab-produces-promising-responses-in-advanced-urothelial-cancer

May 2nd, 2022 - The combination of nab-paclitaxel (Abraxane) and pembrolizumab (Keytruda) produced an encouraging overall response rate (ORR) with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or ...

Targeted Treatment Boom Reshapes Differentiated Thyroid Cancer Landscape
https://www.onclive.com/view/targeted-treatment-boom-reshapes-differentiated-thyroid-cancer-landscape

Apr 18th, 2022 - Differentiated thyroid cancer (DTC) makes up approximately 95% of all thyroid cancers and is becoming more prevalent worldwide.1 A decade ago, treatment options for DTC were limited but today a plethora of targeted treatments are available. There ...

see more →

Patient Education  12 results see all →